CD38 and plasma cell myeloma: Our data demonstrated that CD38KO NK cells have more prominent metabolic profile, increased killing mediated by ADCC against CD38+ multiple myeloma cell lines and patient derived samples and are protected from fratricide mediated by daratumumab (96, 101).